Stephen F. Betz - Feb 28, 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Chief Scientific Officer
Signature: /s/ Marc Wilson, as attorney-in-fact
Stock symbol: CRNX
Transactions as of: Feb 28, 2022
Transactions value $: -$61,617
Form type: 4
Date filed: 3/2/2022, 08:00 PM
Previous filing: Feb 17, 2022
Next filing: Mar 17, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Award	$0	+16.5K	+13.35%	$0.00	140K	Feb 28, 2022	Direct	F1
transaction	CRNX	Common Stock	Sale	-$61.6K	-3.12K	-2.23%	$19.73	137K	Mar 1, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Stock Option (right to buy)	Award	$0	+77K		$0.00	77K	Feb 28, 2022	Common Stock	77K	$20.02	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023.
F2	The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F3	The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022.